Guangzhou Gloria Biosciences Co., Ltd. announced it will receive CNY 200 million in an equity round of funding on May 13, 2022. The transaction include participation from returning investor Harbin Gloria Pharmaceuticals Co., Ltd for 42.12% stake after completion of the transaction. The transaction was approved by the investor in its 17th meeting of the 5th board of directors and the 11th meeting of the 5th board of supervisors, and still needs to be reviewed by the company's general meeting of shareholders.

The company will use CNY 116,000,000 for registered capital and rest for capital reserve. After the completion of this capital increase, the registered capital of company will be changed to CNY 815,186,001.